Results 111 to 120 of about 21,799 (237)

Prescribing biosimilars [PDF]

BMJ, 2018
Aronson, J, Goldacre, B, Ferner, R
openaire   +2 more sources

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, EarlyView.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Biosimilars [PDF]

Zeitschrift für Rheumatologie, 2013
M. Aringer, T. Dörner
  +5 more sources

Tafasitamab as Monotherapy or in Combination in Japanese Patients With B‐Cell Non‐Hodgkin Lymphoma: Results From the Phase 1b J‐MIND Study

Cancer Science, EarlyView.
J‐MIND evaluated the safety and tolerability of tafasitamab, a CD19‐targeting monoclonal antibody, alone or in combination with other therapies in Japanese patients with B‐cell non‐Hodgkin lymphoma (NHL). Most common treatment‐emergent adverse events across all groups were hematological, and no serious tafasitamab treatment‐related or fatal adverse ...
Koji Izutsu, Noriko Fukuhara, Junichiro Yuda, Youko Suehiro, Shigeru Kusumoto, Marie‐Laure Casadebaig, Kazumi Suzukawa, Kentaro Fukushima   +7 more
wiley   +1 more source

The impact of financial incentives promoting biosimilar products in oncology: A quasi-experimental study using administrative data.

PLoS ONE
BackgroundBiosimilars have the potential to save a significant amount of money in cancer treatment costs. However, barriers exist in the adoption of biosimilar products.
Hisashi Itoshima, Daisuke Takada, Etsu Goto, Noriko Sasaki, Susumu Kunisawa, Yuichi Imanaka   +5 more
doaj   +1 more source

Investigating the Effect of Tumour Necrosis Factor Antagonist on Olfaction

Clinical Otolaryngology, EarlyView.
ABSTRACT Objectives Tumour Necrosis factor antagonists is a potent anti‐inflammatory medication and has shown to improve olfactory function in murine models. The primary aim was to determine the effect of TNF antagonists on olfactory performance in humans.
Andreas Espehana, George Macfarlane, Elizabeth Mairenn Garden, Liam Lee, Gabija Klyvyte, Lavandan Jegatheeswaran, Rebecca Davies, Carl Philpott   +7 more
wiley   +1 more source

Inconsistent standard of care for tuberculosis screening and preventive therapy before initiating systemic psoriasis treatment

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives Preventive tuberculosis (TB) therapy before initiating MTX or IL‐17/IL‐23/IL‐12/23p40 inhibitors for latent tuberculosis infection (LTBI) is supported by indirect evidence of TB reactivations with TNF inhibitors. However, direct evidence for MTX or IL‐17/IL‐23/IL‐12/23p40 inhibitors is limited.
Christoph Zeyen, Ruben Heuer, Brit Haecker, Tom Schaberg, Alexander Nast   +4 more
wiley   +1 more source

Impact of adalimumab treatment on impairment of non‐professional activities in psoriasis patients

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives Psoriasis can result in reduced quality of life, work productivity loss, and a significant restriction in non‐professional activities. This study investigates the effects of long‐term treatment with adalimumab regarding work ability, non‐professional activities, and health‐related quality of life in a large real‐word ...
Georgios Kokolakis, Sandra Philipp, Thomas Mosch, Björn Fritz, Robert Sabat   +4 more
wiley   +1 more source

Clinical and Economic Value of a Biosimilar Portfolio to Stakeholders: An Integrative Literature Review

ClinicoEconomics and Outcomes Research
Grace E Fox,1 Mark Bernauer,1 Jennifer M Stephens,1 Bianca Jackson,1 Joshua A Roth,2 Ahmed Shelbaya2,3 1Strategic Market Access, OPEN Health, Bethesda, MD, USA; 2Global Access and Value, Pfizer Inc., New York, NY, USA; 3Department of Epidemiology ...
Fox GE, Bernauer M, Stephens JM, Jackson B, Roth JA, Shelbaya A   +5 more
doaj  

Uptake of biosimilars in China: a retrospective analysis of the case of trastuzumab from 2018 to 2023

Global Health Research and Policy
Background The Chinese biosimilar industry has demonstrated rapid growth in recent years. Limited evidence is available about biosimilar uptake at the national level.
Qiyou Wu, Zhitao Wang, Yihan Fu, Ren Luo, Jing Sun   +4 more
doaj   +1 more source